Choroba resztkowa w przypadku raka HER 2-dodatniego

Ewa Chmielik; Wojciech Olszewski

ISSN: -

Polish Journal of Pathology Supplement

Bieżący suplement Archiwum Polish Journal of Pathology

Wyszukiwanie

2/2021

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

Wytyczne/zalecenia

Choroba resztkowa w przypadku raka HER 2-dodatniego

Ewa Chmielik

¹

,

Wojciech Olszewski

²

Zakład Patologii Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy, Oddział w Gliwicach
Zakład Patologii i Diagnostyki Laboratoryjnej, Narodowy Instytut Onkologii im Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Oddział w Warszawie

Pol J Pathol 2021; 72 Suppl (1): 13-16

Data publikacji online: 2023/02/02

Plik artykułu:

- SPJP-supl-2.pdf [0.82 MB]

Pobierz cytowanie

1. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-1804.

2. Provenzano E. Neoadjuvant Chemotherapy for Breast Cancer: Moving Beyond Pathological Complete Response in the Molecular Age. Acta Med Acad 2021; 50: 88-109.

3. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med 2017 ; 376: 2147-2159.

4. von Minckwitz G, Huang CS, Mano MS, et al.; KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019; 380: 617-628.

5. Kantor O, Bao J, Jaskowiak N, et al. The Prognostic Value of the AJCC 8th Edition Staging System for Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer. Ann Surg Oncol 2020 ; 27: 352-358.

6. Prat A, Fan C, Fernández A, et al. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Med 2015; 13: 303.

7. Foldi J, Mougalian S, Silber A, et al. Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer. Breast Cancer Res Treat 2018; 169: 333-340.

8. Akashi M, Yamaguchi R, Kusano H, et al. ER staining levels affect HER2 staining and heterogeneity. Breast Cancer 2021 ; 28: 720-726.

9. Salgado R, Denkert C, Campbell C, et al. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. JAMA Oncol 2015; 1: 448-454.

10. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-113.

11. Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2018; 19: 40-50.

12. Freitas AJA, Causin RL, Varuzza MB, et al. Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review. Cancers (Basel) 2021; 13: 5477.

13. Mrkonjic M, Berman HK, Done SJ, et al. Breast specimen handling and reporting in the post-neoadjuvant setting: challenges and advances. J Clin Pathol 2019; 72: 120-132.

14. Pastorello RG, Laws A, Grossmith S, et al. Clinico-pathologic predictors of patterns of residual disease following neoadjuvant chemotherapy for breast cancer. Mod Pathol 2021; 34: 875-882.

15. Li X, Wang M, Wang M, et al. Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy. J Breast Cancer 2019; 22: 497-521.

16. Zhang N, Moran MS, Huo Q, et al. The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis. Cancer Invest 2011; 29: 594-598.

17. Mittendorf EA, Wu Y, Scaltriti M, et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009; 15: 7381-7388.

18. Guarneri V, Dieci MV, Barbieri E, et al. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. Ann Oncol 2013; 24: 2990-2994.

19. Katayama A, Miligy IM, Shiino S, et al. Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. Mod Pathol 2021; 34: 1271-1281.

20. Assersohn L, Salter J, Powles TJ, et al. Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res Treat 2003; 82: 113-123.

21. Jones RL, Salter J, A'Hern R, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009; 116: 53-68.

22. Sheri A, Smith IE, Johnston SR, et al. Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. Ann Oncol 2015; 26: 75-80.

23. Matsubara N, Mukai H, Masumoto M, et al. Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR. Breast Cancer Res Treat 2014; 147: 95-102.

Copyright: © 2023 Polish Association of Pathologists and the Polish Branch of the International Academy of Pathology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Choroba resztkowa w przypadku raka HER 2-dodatniego

Ewa Chmielik 1 , Wojciech Olszewski 2

Ewa Chmielik

¹

,

Wojciech Olszewski

²